EGFR and non-small cell lung carcinoma: These assays, including EGFR ctDNA assay in non-small cell lung cancer, have been validated for clinical use and demonstrate the concordance of mutation detection between the primary tumor tissue and plasma ranges from 70–90% [39–41] Previous studies in HPV+ OPSCC have shown detected HPV16 ctDNA at similar frequencies [21–23].